Tags

Type your tag names separated by a space and hit enter

Single intra-articular injection of lightly cross-linked hyaluronic acid reduces knee pain in symptomatic knee osteoarthritis: a multicenter, double-blind, randomized, placebo-controlled trial.
Knee Surg Sports Traumatol Arthrosc. 2019 Jun; 27(6):1992-2002.KS

Abstract

PURPOSE

The primary objective was to demonstrate the safety and effectiveness of Monovisc™ in the relief of joint pain in patients with idiopathic knee OA compared to saline injection. It was hypothesized that patient success, defined as ≥ 50% improvement from baseline and ≥ 20 mm absolute improvement from baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) visual analog scale (VAS) pain score, would be greater in the Monovisc™ group compared to the Saline control group.

METHODS

In this multicenter, double-blind, randomized, placebo-controlled trial, patients with idiopathic, symptomatic, knee OA were randomized to either 4 ml single injection of Monovisc™ or 4 ml injection of 0.9% saline. The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) was used to assess patient outcomes at 2, 4, 8, 12, 20, and 26 weeks post-injection. The primary effectiveness endpoint was a 50% improvement and ≥ 20 mm improvement from baseline in the WOMAC pain through 26 weeks. Secondary outcome measures included a ≥ 20 mm improvement from baseline on the WOMAC physical function, patient global assessment, evaluator global assessment, and knee range of motion.

RESULTS

369 patients (154 male, 215 female) were randomized to either Monovisc™ or saline. The Monovisc™ group had a significantly greater rate of patient success (e.g. ≥ 50% improvement and ≥ 20 mm absolute improvement from baseline in the WOMAC pain through Week 26) compared to saline (p = 0.043).

CONCLUSIONS

Monovisc™, a single-injection intra-articular HA device, is a safe and effective treatment for providing a clinically meaningful reduction in knee pain within 2 weeks. The results of this study support the use of a single injection of hyaluronic acid (Monovisc™) for patients with symptomatic knee OA in patients older than 45 years, as a safe and effective alternative for patients who may want an alternative treatment modality or may not be candidates for partial or total knee replacement.

LEVEL OF EVIDENCE

I, multicenter, double-blind, randomized, placebo-controlled trial.

Authors+Show Affiliations

Orthopaedic Foundation, 2777 Summer Street, Suite 500, Stamford, CT, 06905, USA.Albert Einstein College of Medicine/Montefiore Hospital, Plancher Orthopaedics and Sports Medicine, 1160 Park Avenue, New York, NY, 10128, USA. kplancher@plancherortho.com.

Pub Type(s)

Journal Article
Multicenter Study
Randomized Controlled Trial

Language

eng

PubMed ID

30159738

Citation

Petterson, Stephanie C., and Kevin D. Plancher. "Single Intra-articular Injection of Lightly Cross-linked Hyaluronic Acid Reduces Knee Pain in Symptomatic Knee Osteoarthritis: a Multicenter, Double-blind, Randomized, Placebo-controlled Trial." Knee Surgery, Sports Traumatology, Arthroscopy : Official Journal of the ESSKA, vol. 27, no. 6, 2019, pp. 1992-2002.
Petterson SC, Plancher KD. Single intra-articular injection of lightly cross-linked hyaluronic acid reduces knee pain in symptomatic knee osteoarthritis: a multicenter, double-blind, randomized, placebo-controlled trial. Knee Surg Sports Traumatol Arthrosc. 2019;27(6):1992-2002.
Petterson, S. C., & Plancher, K. D. (2019). Single intra-articular injection of lightly cross-linked hyaluronic acid reduces knee pain in symptomatic knee osteoarthritis: a multicenter, double-blind, randomized, placebo-controlled trial. Knee Surgery, Sports Traumatology, Arthroscopy : Official Journal of the ESSKA, 27(6), 1992-2002. https://doi.org/10.1007/s00167-018-5114-0
Petterson SC, Plancher KD. Single Intra-articular Injection of Lightly Cross-linked Hyaluronic Acid Reduces Knee Pain in Symptomatic Knee Osteoarthritis: a Multicenter, Double-blind, Randomized, Placebo-controlled Trial. Knee Surg Sports Traumatol Arthrosc. 2019;27(6):1992-2002. PubMed PMID: 30159738.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Single intra-articular injection of lightly cross-linked hyaluronic acid reduces knee pain in symptomatic knee osteoarthritis: a multicenter, double-blind, randomized, placebo-controlled trial. AU - Petterson,Stephanie C, AU - Plancher,Kevin D, Y1 - 2018/08/29/ PY - 2018/04/26/received PY - 2018/08/10/accepted PY - 2018/8/31/pubmed PY - 2019/8/20/medline PY - 2018/8/31/entrez KW - Hyaluronic acid KW - Intra-articular injection KW - Knee joint pain KW - Knee osteoarthritis KW - Monovisc™ SP - 1992 EP - 2002 JF - Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA JO - Knee Surg Sports Traumatol Arthrosc VL - 27 IS - 6 N2 - PURPOSE: The primary objective was to demonstrate the safety and effectiveness of Monovisc™ in the relief of joint pain in patients with idiopathic knee OA compared to saline injection. It was hypothesized that patient success, defined as ≥ 50% improvement from baseline and ≥ 20 mm absolute improvement from baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) visual analog scale (VAS) pain score, would be greater in the Monovisc™ group compared to the Saline control group. METHODS: In this multicenter, double-blind, randomized, placebo-controlled trial, patients with idiopathic, symptomatic, knee OA were randomized to either 4 ml single injection of Monovisc™ or 4 ml injection of 0.9% saline. The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) was used to assess patient outcomes at 2, 4, 8, 12, 20, and 26 weeks post-injection. The primary effectiveness endpoint was a 50% improvement and ≥ 20 mm improvement from baseline in the WOMAC pain through 26 weeks. Secondary outcome measures included a ≥ 20 mm improvement from baseline on the WOMAC physical function, patient global assessment, evaluator global assessment, and knee range of motion. RESULTS: 369 patients (154 male, 215 female) were randomized to either Monovisc™ or saline. The Monovisc™ group had a significantly greater rate of patient success (e.g. ≥ 50% improvement and ≥ 20 mm absolute improvement from baseline in the WOMAC pain through Week 26) compared to saline (p = 0.043). CONCLUSIONS: Monovisc™, a single-injection intra-articular HA device, is a safe and effective treatment for providing a clinically meaningful reduction in knee pain within 2 weeks. The results of this study support the use of a single injection of hyaluronic acid (Monovisc™) for patients with symptomatic knee OA in patients older than 45 years, as a safe and effective alternative for patients who may want an alternative treatment modality or may not be candidates for partial or total knee replacement. LEVEL OF EVIDENCE: I, multicenter, double-blind, randomized, placebo-controlled trial. SN - 1433-7347 UR - https://www.unboundmedicine.com/medline/citation/30159738/Single_intra_articular_injection_of_lightly_cross_linked_hyaluronic_acid_reduces_knee_pain_in_symptomatic_knee_osteoarthritis:_a_multicenter_double_blind_randomized_placebo_controlled_trial_ L2 - https://dx.doi.org/10.1007/s00167-018-5114-0 DB - PRIME DP - Unbound Medicine ER -